Rectify Pharmaceuticals is a technology company.
Rectify Pharmaceuticals has raised $100.0M across 1 funding round.
Rectify Pharmaceuticals has raised $100.0M in total across 1 funding round.
Rectify Pharmaceuticals has raised $100.0M in total across 1 funding round.
Rectify Pharmaceuticals's investors include Advanced Technology Ventures, Agent Capital, Arcus Ventures, Atlas Venture, Forbion, Longwood Fund, OrbiMed, Pfizer Venture Investments.
Rectify Pharmaceuticals is a development-stage biotechnology company headquartered in Cambridge, Massachusetts, focused on developing Positive Functional Modulators (PFMs)—small-molecule therapeutics that restore and enhance ABC transporter function to treat serious genetic diseases, including primary sclerosing cholangitis (PSC), cardio-renal-metabolic disorders, and neurodegenerative conditions.[1][2][5] The company serves patients with ABC transporter-mediated diseases, addressing the underlying cause of dysfunction in this 48-member superfamily of membrane proteins, where no approved therapies exist outside CFTR modulators.[1][2] Launched in 2021 with a $100 million Series A financing co-led by Atlas Venture, Omega Funds, Forbion, and Longwood Fund, Rectify is advancing its lead hepatobiliary program (targeting ABCB4 and BSEP for PSC) through IND-enabling studies, with plans for human proof-of-concept trials.[2][5]
Rectify Pharmaceuticals was founded in 2020 by Atlas Venture, with Jonathan Moore, Ph.D., as a founding scientist and Chief Scientific Officer; Moore previously pioneered CFTR-targeted therapies for cystic fibrosis at Vertex Pharmaceuticals.[2] Rajesh Devraj, Ph.D., President and CEO and a venture partner at Atlas Venture, leads the company, emphasizing disease-modifying therapies for ABC transporter deficiencies.[2] The idea emerged from applying proven CFTR modulation success to the broader, untapped ABC transporter family, leading to the company's 2021 launch with $100 million in seed and Series A funding to build a pipeline across liver, biliary, eye, and CNS diseases.[1][2]
Rectify rides the wave of precision medicine in membrane protein modulation, extending CFTR successes (e.g., Vertex's cystic fibrosis drugs) to the undrugged ABC transporter class, which underlies diseases affecting millions in liver, kidney, heart, and CNS areas.[1][2] Timing aligns with surging demand for disease-modifying therapies amid rising cardio-renal-metabolic burdens—a top global cause of death—and advances in small-molecule screening platforms.[5] Market forces like orphan drug incentives for rare hepatobiliary conditions (e.g., PSC) and NASH epidemic favor Rectify, positioning it to influence biotech by pioneering PFM chemistry applicable beyond ABC transporters to other membrane proteins.[5]
Rectify is poised to deliver first-in-class PFMs, with its PSC lead candidate advancing to IND submission and clinical trials in 2025-2026, potentially yielding human POC data soon after.[2][5] Trends like AI-driven protein engineering and combo therapies for metabolic diseases will accelerate its pipeline expansion into CRM and neurodegeneration.[5] As the first ABC modulator beyond CFTR, Rectify could reshape treatment paradigms for transporter-mediated diseases, amplifying Atlas Venture's biotech impact while scaling from its $100M war chest toward multi-asset proof-of-concept milestones.[1][2] This positions Rectify as a key player rectifying unmet needs in precision biotech.
Rectify Pharmaceuticals has raised $100.0M across 1 funding round. Most recently, it raised $100.0M Series A in October 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2021 | $100.0M Series A | Advanced Technology Ventures, Agent Capital, Arcus Ventures, Atlas Venture, Forbion, Longwood Fund, OrbiMed, Pfizer Venture Investments |